Safety and Efficacy of Ankaferd Hemostat (ABS) in the Chemotherapy-Induced Oral Mucositis

M. Hilmi ATAY¹, Nevin A. ASLAN¹, Sude AKTIMUR¹, Piltan BUYUKKAYA¹, Engin KELKITLI¹, Mehmet TURGUT¹, Ibrahim HAZNEDAROGLU²

¹ Ondokuz Mayıs University, Faculty of Medicine, Department of Hematology, Samsun
² Hacettepe University, Faculty of Medicine, Department of Hematology, Ankara, TURKEY

ABSTRACT

Oral mucositis, characterized by ulcerative lesions in the oral mucosa of patients undergoing chemotherapy, is currently considered to be the most severe complication of anti-cancer therapy which is affecting 40-80% of those patients. Ankaferd hemostat, (ABS) is the first topical hemostatic agent regarding the red blood cell (RBC)-fibrinogen interactions tested in the clinical trials. ABS also has pleiotropic effects particularly in the tissue healing and has anti-infective properties. The aim of this study is to assess the safety and efficacy of ABS in the management of chemotherapy-induced oral mucositis in adult patients with hematological malignancies. ABS was topically applied to the patients with grade 3-4 mucositis according to the WHO classification. Patients were said to mouthwash and swallow the five milliliters of ABS. Twenty patients with oral mucositis were evaluated. Eleven patients with acute myeloid leukaemia, four acute lymphoblastic leukaemia, three non-hodgkin lymphoma, one hemophagocytosis with acute myeloid leukaemia and one hemophagocytosis were included in study. Median extract amount was calculated as 74.50 ml (30-100 ml) and median healing time was 6.6 days (3-10). Consequently, ABS is an effective agent in the treatment of chemotherapy related severe oral mucositis in patients with hematological malignancies. Further experimental and clinical trials about ABS shall focus on the interrelationships between proteomic content, fibrinogen gamma, and vital erythroid aggregation due to ABS.

Keywords: Oral mucositis, Chemotherapy, ABS, Tissue healing

ÖZET

Kemoterapiye Bağlı Gelişen Oral Mukozitte Ankaferd Hemostatın (ABS) Güvenliği ve Etkinliği


Anahtar Kelimeler: Oral mukozit, Kemoterapi, ABS, Doku iyileşmesi
INTRODUCTION

Oral mucosa is affected from chemotherapeutics easily because of its’ high cell-turnover. Oral mucositis, characterized by ulcerative lesions in the mucosa of patients undergoing chemotherapy, is currently considered to be the most severe complication of anti-cancer therapy. It is affecting 40-80% of patients who are receiving chemotherapy. Clinical aggressiveness of oral mucositis can affect the nutritional status, proper chemotherapy administration and quality of life of the affected patients.

ABS is the first topical hemostatic agent regarding the red blood cell (RBC)-fibrinogen interactions tested in the clinical trials. ABS is composed of standardized plant extracts including Alpinia officinarum, Glycyrrhiza glabra, Thymus vulgaris, Urtica dioica and Vitis vinifera. ABS induced pharmacological modulation of essential erythroid proteins (ankyrin, spectrin, actin) can cause vital erythroid aggregation via acting on fibrinogen gamma. ABS has pleiotropic effects particularly in the tissue healing and has also anti-infective properties.

In spite of being one of the most investigated subjects among supportive care in chemotherapy patients, none of the treatment alternatives has been found effective in the treatment of chemotherapy-induced oral mucositis. The aim of this study is to assess the safety and efficacy of ABS in the management of chemotherapy-induced oral mucositis in adult patients with hematological malignancies. To evaluate the role of topical ABS application in the management of oral mucositis is highly important for the underlying malignant disease prognosis because the untreated severe ulcers may lead to temporary or permanent treatment interruption which can complicate the underlying malignant disease control and treatment.

PATIENTS AND METHODS

Twenty patients with oral mucositis of grade 3-4 according to the WHO classification (Table 1). After chemotherapy between the dates of 1/10/2012-01/11/2014 in the hematology service of Ondokuz Mayıs University Hospital, were included in this study. All of these patients were taking protective chlorhexidine gluconate mouthwash since the chemotherapy initiation. Only after patients developed oral mucositis they used only Ankaferd. Age and gender of patients, type of the underlying malignant disease and used chemotherapeutic drugs, frequency, amount and duration of ABS use and healing time of oral mucositis were recorded. The study protocol was approved by the Ethics Committee of Ondokuz Mayıs University (OMU KAEK No: 2015/233).

Table 1. WHO Oral Mucositis Grading Scale

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 (none)</td>
<td>None</td>
</tr>
<tr>
<td>I (mild)</td>
<td>Oral soreness, erythema</td>
</tr>
<tr>
<td>II (moderate)</td>
<td>Oral erythema, ulcers, solid diet tolerated</td>
</tr>
<tr>
<td>III (severe)</td>
<td>Oral ulcers, liquid diet only</td>
</tr>
<tr>
<td>IV (life-threatening)</td>
<td>Oral alimentation impossible</td>
</tr>
</tbody>
</table>

Statistical Analysis

All statistical analyses were conducted with the SPSS statistical package for Windows version 15.0 (SPSS Inc., Chicago, IL, USA). All continuous variables were shown by mean ±SD. Intergroup comparison of the non-parametric data was used Mann-Whitney U test. P< 0.05 was considered statistically significant.

RESULTS

Twenty patients with oral mucositis (8 male and 12 female) were evaluated. Median age of the patients was 43.6 (19-60) years. The underlying malignant diseases were: acute myeloid leukemia (11 patients), acute lymphoblastic leukemia (4 patients), non-Hodgkin lymphoma (3 patients), hemophagocytosis with acute myeloid leukemia (1 patient) and hemophagocytosis (1 patient). Eleven patients had used ABS twice in a day, five patients had used ABS three times in a day and four patients had used ABS four times in a day. The amount of used ABS was 30 ml in four patients, 50 ml in three patients,
60 ml in one patient and 100 ml in nine patients. Median extract amount was calculated as 74.50 ml (30-100 ml) and median healing time was 6.6 days (3-10 days). Except for the temporary metallic taste, no adverse effect was observed in patients. Characteristics of patients and used chemotherapeutics and ABS treatments are shown in Table 2.

Patients were divided into two groups according to the total drug dose as high and low. High doses of medication intake was associated with a prolonged recovery time. It is interpreted as a reasonable result because with the increase in severity of oral mucositis, drug dose and recovery time are also needed to be increased. The small number of the study group and lack of a control group may have influenced our statistical results.

**DISCUSSION**

Next-generation RBC-related hemostatics, such as ABS nanohemostat, was designed for the essential treatment of life-threatening bleedings by acting on RBCs and restoring physiological hemostasis. Prohemostatic and antithrombin activi-
ties of ABS are linked to fibrinogen gamma chain and prothrombin by functional proteomic analyses. Those unique hemostatic properties of ABS provide a balanced hemostasis representing a basis for physiological wound healing. The proteomics of the structural and functional properties of the proteins, that related to the wound healing, should also be matched with the already established proteomics of ABS. Randomised clinical trials (RCT) showed the safety and efficacy of ABS for the control of clinical hemorrhages in a wide variety of settings. However, there is no RCT related to wound healing effect of ABS.

Experimental trials showed that ABS is effective in wound healing process. Aktaş et. al has also demonstrated that applying ABS after tooth extraction resulted as increased secretion of some factors which has roles in early phase of wound healing. These factors were collagen type 1, collagen type 3, smooth muscle actin, fibronectin, beta 2 microglobulin, vascular endothelial growth factor and cyclooxygenase-2. As a result, with the help of these mechanisms, ABS provide rapid wound healing. Moreover, ABS can cause polymorph nuclear leukocyte and mono-nuclear leukocyte infiltrations, vascularisation and fibroblast proliferation in mucosal tissue which can also have a role in facilitating the wound healing. Kaya et al. found that topically used ABS decreased the wound diameter and inflammation grade and also increased the tissue fibrosis and wound contraction on the burned wounds.

Bacteria and fungi can be isolated from blood and oral cavity cultures in some patients with oral mucositis. The most common bacteria that were isolated from cultures are Gram negative bacteria, aerobes and fungi (Candida albicans). There are in vitro studies which has showed antibacterial and antifungal activity of ABS. When ABS is added to the culture medium, it inhibits colonies of Acinetobacter, Escherichia coli and Pseudomonas species growth.

Numerous treatment protocols and preventing methods had been tested on the patients with oral mucositis. There is only one drug which is containing palifermin, was approved by the Food and Drug Administration (FDA) in the USA for the prevention of oral mucositis. Palifermin is a recombinant human keratinocyte growth factor (KGF) derivative. This drug was approved for patients with hematological malignancy undergoing high-dose chemotherapy followed by stem cell transplantation. However side effects such as pain, arthralgia and dysaesthesia were reported. Other studies including allopurinol, chlorhexidine and hydrogen peroxide did not show any benefit of those drugs in mucositis treatment. Maltodextrin, sodium hyaluronidase, alcohol and gelclair which is containing anesthetic are used because of their mucosal barrier properties. But gelclair did not have any shown superiority compared to the other drugs. There is limited number of studies in the literature about prevention and treatment of oral mucositis with herbal medicine. In those studies decrease in the oral mucositis with the use of those herbal medicines have already been reported but no information was given about the healing time. In a study by Abdulrhman M, and et. al. honey and a mixture of honey, beeswax, and olive oil-propolis extract was used in pediatric group of grade 2-3 oral mucositis patients, healing time was found to be shorter.

UK Oral Mucositis in Cancer Group give some suggestions for grade 3-4 mucositis patients:
1) If there is pain use powerful analgesics (such as morphine sulphate and oxycodone), if those are ineffective fentanyl patches can be used, 2) If there is a decrease in oral feeding, intravenous or enteral feeding support should be considered, 3) 4-10 times a day oral Caphosol solution (calcium and phosphate ions) should be used. Mouthwash with gelclair (a coating protectant) is needed before each meal, 4) Mouthwash with diluted tranexamic acid should be done 4-6 times a day if there is bleeding, 5) If there is fungal infection, use anti-fungal agent (such as fluconazole and posaconazole). If there is viral infection, use anti-viral agent such as acyclovir. If there is bacterial infection, use anti-bacterial antibiotics.

There are few publications which reported the activity of ABS on chemotherapy related oral mucositis. The first one was a case report about a patient with refractory AML whose haemorrhagic oral mucositis had been recovered in two days with ABS application. A recent clinical study by...
Patroglu et al. has demonstrated that topical ABS application at the beginning of the chemotherapy was provided less oral mucositis when compared to the control group.29

Chemotherapy-related oral mucositis may develop within 7-10 days after the end of the chemotherapy. Complete recovery is seen in about two weeks.11 In this study, with the use of ABS, the median healing time was 6.6 days. Therefore, the healing duration of oral mucositis was shorter than the other agents with the topical ABS application. And also the hemorrhages from oral mucositis lesions were recovered within two days with the application of ABS (Figure 1A and B). Therefore, its hemostatic efficacy is an important benefit, in addition to its antibacterial and wound healing properties. There are two limitations in this study. First one is the lack of control group for the comparison of these findings. Second one is the diversity of diseases of the patients participating the study and treatment differences may have influenced the results of this study.

Conclusion

ABS is an effective agent in the chemotherapy-related severe oral mucositis treatment of the patients with hematological malignancies. ABS shortens the healing time with acceptable side effects. It is the first study that shows effectiveness of ABS application in chemotherapy related oral mucositis in adult patients. We hope that further trials that emphasize the importance of ABS use in the management of chemotherapy related oral mucositis will take place and also includes the interrelationships between proteomic content, fibrinogen gamma, and vital erythroid aggregation due to ABS.

REFERENCES


